Global One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market when the promise seems so great, but the evidence remains so patchy. So far, top tier regulators such as the US FDA and…
Global Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about its potential as a revolutionary, perhaps even decisive, new pillar in the war on cancer. Five years later, however, many are still left…
Europe Building on points developed in his 2020 PharmaBoardroom interview, Professor Nicolaus Kröger of the European Society for Blood and Marrow Transplantation (EBMT) outlines the progress made by the multi-stakeholder GoCART Coalition towards greater harmonisation of cell and gene therapy research in Europe, the challenges of integrating patient-reported outcomes into its…
Europe Professor Nicolaus Kröger, president of the European Society for Blood and Marrow Transplantation (EBMT) introduces the multi-stakeholder GoCART Coalition and the impact that it stands to have on the cell and gene therapy field in Europe. It was critical to build a coalition that is win-win for everyone Nicolaus,…
See our Cookie Privacy Policy Here
